Introduction

Degos disease, also known as malignant atrophic papulosis (MAP), is a rare, often fatal, occlusive vasculopathy.¹² Its most recognisable symptom is the presence of porcelain-white papules surrounded by an erythematous rim, typically appearing on the skin before systemic involvement emerges.¹³ While dermatologic signs may appear deceptively benign, visceral disease transforms the condition into a life-threatening disorder.²

Gastrointestinal (GI) complications occur in nearly half of MAP cases and are the primary driver of mortality.^2,4 The disease can cause small-bowel infarction, ulceration, and multiple perforations, culminating in peritonitis. Once perforation occurs, outcomes are grim.⁴ Case reports describe patients presenting with abdominal crises after months of unrecognised skin lesions, eventually succumbing to recurrent perforations and overwhelming sepsis despite aggressive surgical care.⁴

Early recognition is therefore critical. Suspicious cutaneous lesions, coupled with suggestive imaging or endoscopic findings, should prompt vigilance for intestinal involvement.² Yet, when bowel perforation occurs, emergency surgical intervention becomes unavoidable. Unfortunately, even prompt surgery cannot cure the underlying systemic disease, which continues to generate new ischemic events.^2,4

Pathophysiology of gastrointestinal involvement

Degos disease is a small-vessel endovasculopathy characterised by endothelial injury, thrombotic occlusion, and complement activation, particularly deposition of the terminal complement complex C5b-9.² This environment of endothelial dysfunction and microthrombosis narrows vascular lumens in both skin and viscera.^2,5

The intestinal vasculature is especially vulnerable. Small end-arterial branches feeding the small intestine often become focally blocked, first reducing blood flow to the mucosa, before advancing to full-thickness necrosis.² As the bowel wall dies, it weakens and eventually ruptures, allowing intestinal contents to leak into the peritoneal cavity. This explains the sudden shift from vague abdominal pain to fulminant peritonitis. Multifocality is typical; while one area perforates, another may already be thrombosing, which explains recurrent emergencies after apparently adequate resections.⁴

Histopathology reinforces this mechanism. Wedge-shaped infarcts with fibrin thrombi are seen, often with little inflammatory infiltrate. This supports a thrombo-occlusive, rather than primarily vasculitic, process.² Complement inhibition studies have also highlighted the central role of terminal complement in driving these vascular lesions.²

The small intestine, particularly the jejunum and ileum, is the most frequent site of injury. Colon and stomach involvement occurs less often, but simultaneous multi-level lesions are possible. The clustering of small-bowel perforations across case reports underscores why intestinal disease is the leading cause of death in systemic MAP.^2,4

Clinical presentation and diagnostic challenges

Symptoms

Symptoms usually present abruptly. Patients often first experience widespread or cramping abdominal pain that seems more severe than what physical examination suggests. As the lack of blood flow worsens and tissue dies, the discomfort becomes more focused, eventually leading to peritoneal irritation characterised by tenderness, guarding, and rebound pain. Some patients initially mimic bowel obstruction, with nausea, vomiting, and distension, before perforation becomes evident. Recurrence is common, reflecting the multifocal nature of vascular injury.^2,4

Role of imaging and endoscopy

CT imaging often reveals nonspecific findings like segmental bowel wall thickening, hypoenhancement, or free air where perforation has occurred. Mesenteric angiography may occasionally show abrupt cutoffs in small arteries, but the microvascular disease is usually below the resolution of angiography. Endoscopy may reveal antimesenteric ulcerations or pale ischemic patches, though its diagnostic yield is limited.²

Diagnostic difficulties

The rarity of Degos disease makes diagnosis elusive. Its abdominal crises are easily mistaken for more common conditions such as mesenteric ischemia, Crohn’s disease, or perforated ulcer. Even when cutaneous lesions are present, their significance is often missed. Intraoperative discovery of multiple serosal plaques and noncontiguous perforations should raise suspicion for MAP, but by this stage, many patients have already undergone repeated laparotomies.^2,4

Surgical indications and approaches

Absolute indications

In systemic Degos disease, deterioration is often swift. The following are widely accepted triggers for immediate operative management:^2,4

• Free perforation with generalised peritonitis (often multifocal)
• Radiologic or intraoperative evidence of transmural necrosis (non-viable bowel)
• Uncontrolled intraluminal or intra-abdominal bleeding unresponsive to resuscitation
• Septic shock or progressive peritonitis despite antibiotics and source control attempts

Case series and narrative reviews consistently report that bowel perforation and peritonitis are the leading causes of death due to Degos disease, and that delay to laparotomy worsens outcomes.⁴

Surgical options

Exploratory laparotomy is the default in unstable patients; diagnostic laparoscopy can be valuable in stable patients to confirm multifocal ischemic plaques and guide timely conversion. Intraoperative findings often include scattered antimesenteric ulcers, pale “porcelain” serosal patches, and multiple small perforations, hallmarks of the disease’s patchy thrombo-occlusive microangiopathy.^2,4

When resection is required, strategy should reflect the field-defect nature of perfusion injury:

• Segmental resection of frankly necrotic or perforated segments with a low threshold for exteriorisation (end or loop stoma) rather than primary anastomosis in unstable physiology or poor tissue quality. Anastomotic healing is jeopardised by ongoing microvascular thrombosis, and recurrent, noncontiguous perforations are well documented^2,4
• Damage-control surgery (DCS) is appropriate for septic or hemodynamically fragile patients: rapid source control, contamination limitation, temporary abdominal closure, and planned second-look once physiology improves. Given the propensity for new ischemic foci, re-exploration within 24-48 hours helps reassess bowel viability and decide on restoration of continuity versus diversion²
• Bowel-sparing mindset: avoid over-resection in the face of skip lesions to reduce the risk of short-bowel syndrome; resect only clearly non-viable bowel and manage borderline segments with damage-control principles and re-look surgery²

Considerations in intraoperative decision-making

• Fragile, under-perfused tissues: Expect poor serosal turgor and punctate antimesenteric ischemia. Choose atraumatic handling, generous margins around overt necrosis, and wide drainage if contamination is significant. Primary anastomosis should be reserved for well-perfused bowel in stable patients²
• Recurrence risk and multifocality: Even after technically sound resections, new perforations may develop at distant sites because the underlying endovasculopathy persists. Counsel teams and families that surgery treats the complication, not the disease biology, and anticipate re-operations⁴
• Adjunct medical therapy: While surgery is the cornerstone for perforation and necrosis, adjuncts aimed at the disease mechanism (e.g., terminal complement inhibition with eculizumab; prostacyclin analogs such as treprostinil; selective use of anticoagulation/antiplatelet agents) are discussed in contemporary reviews and reports. These may be initiated or continued perioperatively in collaboration with dermatology/rheumatology, recognising variable responses and occasional early failures^2,5

Postoperative management and outcomes

Complications and the risk of re-perforation

After emergency surgery for MAP-related bowel catastrophe, complications are driven by the disease’s multifocal, thrombo-occlusive biology rather than any single operative misstep. Common early problems include persistent sepsis, intra-abdominal abscess, enteric fistula, anastomotic failure, and most ominously new, noncontiguous perforations that arise despite apparently healthy margins at the index operation. Case reports consistently document repeat laparotomies for fresh perforations within days to weeks, underscoring the need for planned re-assessment when physiology allows.^2,4

Role of immunosuppressive and antithrombotic therapy after surgery

Since surgery treats the complication, not the systemic vasculopathy, postoperative care should promptly address the underlying endothelial/complement injury:

• Complement inhibition (eculizumab): Pathology studies show dense C5b-9 (terminal complement) deposition in MAP lesions, providing a mechanistic rationale for eculizumab. Case reports/series describe disease stabilisation or improvement with C5 blockade, though responses are variable and relapses occur; critically ill patients may still succumb despite treatment. Coordination with haematology/dermatology is vital, and meningococcal prophylaxis is mandatory²
• Prostacyclin analogs (treprostinil): Several reports suggest symptomatic and lesion-level improvement with treprostinil, including as “rescue” when eculizumab fails. Haemodynamic effects (platelet inhibition, vasodilation) may counter microthrombosis, but evidence remains limited to observational data²
• Antiplatelet/anticoagulant therapy: Historical series report use of aspirin and dipyridamole, sometimes with heparin/LMWH, aiming to blunt the thrombo-occlusive tendency. While widely practiced, high-quality efficacy data is lacking; choices should be individualised to bleeding risk (especially post-resection) and revisited at each staged operation²

In the immediate postoperative window, a practical bundle includes: restart/commence disease-modifying therapy (C5 inhibition ± treprostinil) once sepsis is controlled and vaccinations/antibiotic prophylaxis are in place; maintain venous thromboembolism prophylaxis; use a low threshold for re-imaging when pain or inflammatory markers rise, given the propensity for new ischemic segments²

Prognosis and survival from reported cases

Systemic MAP carries a poor prognosis, with bowel perforation the leading cause of death.^2,4 Classical reviews note that once systemic involvement declares itself, survival has historically been measured in months to a few years, with paediatric and adult fatal cases with recurrent perforations being well documented. Contemporary series suggest outcomes may be improving in selected patients receiving complement and prostacyclin-based regimens, but evidence remains low-level and heterogeneous.^2,5 Families should be counseled that even after seemingly definitive surgery, late re-perforation and extra-intestinal events (neurologic, cardiac) can determine the course.^2,4

Summary

Gastrointestinal involvement in Degos disease represents the most feared and lethal manifestation of this rare vasculopathy.^2,4 When perforation, infarction, or uncontrolled bleeding occurs, surgical intervention is often the only lifesaving option, despite the high risk of recurrence and postoperative complications. Optimal care demands a multidisciplinary approach - surgeons, pathologists, rheumatologists, and intensivists working together to balance emergency source control with systemic disease-modifying therapy.^2,5 Above all, early recognition of skin and abdominal signs, rapid operative decision-making, and integration of novel targeted treatments such as complement inhibition and prostacyclin analogs are crucial to improving outcomes. Continued reporting of cases and collaborative research remain essential to refine management strategies and to alter what has historically been a grim prognosis.^2,4